Heart failure & cardiomyopathiesRandomised controlled trial
Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial
- Baseline characteristics report of the FINEARTS-HF randomised trial
- placebo-controlled
Authors' conclusion
FINEARTS-HF has enrolled a broad range of high-risk patients with HFmrEF and HFpEF.
Study context
- Population
- Symptomatic heart failure (HF), left ventricular ejection fraction (LVEF) ≥40%, eGFR ≥ 25 ml/min/1.73 m², elevated natriuretic peptides and structural heart disease (HFmrEF/HFpEF)
- Participants
- 6,001 participants
- Comparison
- Finerenone vs placebo
Primary result
As reported in the abstract
Baseline characteristics · baseline
- Age, mean ± SD (years)
- 72 ± 10
- Women
- 46%
- NYHA class II
- 69%
- LVEF, mean ± SD (range)
- 53 ± 8% (range 34-84%)
- LVEF <50%
- 36%
- LVEF ≥50%
- 64%
- NT-proBNP, median (IQR), pg/ml
- 1041 (449-1946)
- Enrolled during or within 7 days of a worsening HF event
- 1219 (20%)
- Enrolled within 3 months of a worsening HF event
- 3247 (54%)
Original publication
Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial. Eur J Heart Fail. Published 11 May 2024. doi:10.1002/ejhf.3266
Summarised from the published abstract; every number is checked against it